EPISODE · May 17, 2021 · 9 MIN
GenBio, Inc. Discusses Entering the 191 Billion Dollar Anti-Inflammatory Market, Potential of Their Research, Crowdfunding Offering, and Their Strategic Partnership with Dakshidin Corp. (OTC:Pink DKSC) on The Stock Day Podcast
from Stock Day Media · host Stock Day Media
The Stock Day Podcast welcomed GenBio, Inc. and Dakshidin Corp (OTC Pink: DKSC)("the Company"). Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company with unrivaled (and possibly unique) research expertise based on an unexpected yet vitally important medical research breakthrough - described by the US scientific team as “never seen before”, and Dakshidin Corp. CEO, Chris Haigh, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
Embed this episode
Ready to play
GenBio, Inc. Discusses Entering the 191 Billion Dollar Anti-Inflammatory Market, Potential of Their Research, Crowdfunding Offering, and Their Strategic Partnership with Dakshidin Corp. (OTC:Pink DKSC) on The Stock Day Podcast
No transcript for this episode yet
Similar Episodes
No similar episodes found.